Recital 4, Regulation (EU) 2024/568

In forcesince 7 Feb 2024

The fees payable to the Agency should be proportionate to the work carried out in relation to obtaining and maintaining a Union marketing authorisation. The fees should be based on a transparent evaluation of the Agency’s estimations and forecasts as regards the workload and related costs for that work, as well as on an evaluation of the costs of the services provided to the Agency by the competent authorities of the Member States that are responsible for regulating medicinal products, which act as rapporteurs and, where applicable, co-rapporteurs appointed by the scientific committees of the Agency. The fees, charges and fee structure should take into account any objective information on costs or on changes to the regulatory framework.